P & F Industries, Inc. (PFIN) stock prices updated...
 

P & F Industries, Inc. stock price

P & F Industries, Inc. latest news:


  • 09/11/2017 11:19:47

    Dow industrials rally 260 points, retake 22,000 level, as worries over Hurricane Irma, North Korea abate

    U.S. stock-index benchmarks jump on Monday, as Hurricane Irma hit Florida with less force than expected and North Korea failed to conduct another nuclear missile test over the weekend, helping to lure investors into buying assets perceived as risky like equities. The Dow Jones Industrial Average traded 262 points, or 1.2%, at 22,060, while the S&P 500 index climbed 1.1% at 2,488, putting the broad-market gauge within range of its intraday high. The Nasdaq Composite Index rallied 1.1% at 6,432, was within range of its all-time closing high. In corporate news, investors awaited the debut of Apple Inc.'s new iPhone 8 on Tuesday. In other corporate news, shares of Teva Pharmaceutical Industries Ltd. were up, after the Israeli drug company on Monday named Lundbeck's Kare Schultz as its new chief executive. Meanwhile, Wall Street was marking the anniversary of 9/11. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/11/2017 10:42:41

    Dow industrials rally 250 points, retake 22,000 level, as worries over Hurricane Irma, North Korea abate

    U.S. stock-index benchmarks jump on Monday, as Hurricane Irma hit Florida with less force than expected and North Korea failed to conduct another nuclear missile test over the weekend, helping to lure investors into buying assets perceived as risky like equities. The Dow Jones Industrial Average traded 250 points, or 1.2%, at 22,054, while the S&P 500 index climbed 1.1% at 2,487, putting the broad-market gauge within range of its intraday high. The Nasdaq Composite Index rallied 1.1% at 6,432, was within range of its all-time closing high. In corporate news, investors awaited the debut of Apple Inc.'s new iPhone 8 on Tuesday. In other corporate news, shares of Teva Pharmaceutical Industries Ltd. were up, after the Israeli drug company on Monday named Lundbeck's Kare Schultz as its new chief executive. Meanwhile, Wall Street was marking the anniversary of 9/11. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/11/2017 08:08:13

    Dow industrials rally 200 points, retake 22,000 level, as worries over Hurricane Irma, North Korea abate

    U.S. stock-index benchmarks jumped at the open on Monday, as Hurricane Irma hit Florida with less force than expected and North Korea failed to conduct another nuclear missile test over the weekend, helping to lure investors into buying assets perceived as risky like equities. The Dow Jones Industrial Average opened up 201 points, or 0.9%, at 22,010, while the S&P 500 index climbed 0.9% at 2,483, putting the broad-market gauge within range of its closing high. The Nasdaq Composite Index rallied 1.2% at 6,438, also within range of an all-time closing high. In corporate news, investors awaited the debut of Apple Inc.'s new iPhone 8 on Tuesday. In other corporate news, shares of Teva Pharmaceutical Industries Ltd. were up, after the Israeli drug company on Monday named Lundbeck's Kare Schultz as its new chief executive. Meanwhile, Wall Street was marking the anniversary of 9/11. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/11/2017 07:46:16

    Dow industrials rally nearly 200 points as worries over Hurricane Irma, North Korea abate

    U.S. stock-index benchmarks jumped at the open on Monday, as Hurricane Irma hit Florida with less force than expected and North Korea failed to conduct another nuclear missile test over the weekend, helping to lure investors into buying assets perceived as risky like equities. The Dow Jones Industrial Average opened up 190 points, or 0.9%, at 21,986, while the S&P 500 index climbed 0.8% at 2,481, putting the broad-market gauge within range of its closing high. The Nasdaq Composite Index rallied 1.1% at 6,432, also within range of an all-time closing high. In corporate news, investors awaited the debut of Apple Inc.'s new iPhone 8 on Tuesday. In other corporate news, shares of Teva Pharmaceutical Industries Ltd. were up, after the Israeli drug company on Monday named Lundbeck's Kare Schultz as its new chief executive. Meanwhile, Wall Street was marking the anniversary of 9/11. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/17/2017 10:59:47

    Reps. Cummings, Welch to launch investigation into multiple sclerosis drug prices

    Rep. Elijah Cummings (D-Md.) and Rep. Peter Welch (D-Vt.) said Thursday morning that they are launching an investigation into multiple sclerosis drug prices, and have sent letters to seven pharmaceutical companies about their pricing strategies. Letters were sent to Bayer AG , Biogen Inc. , Merck & Co.'s EMD Serono, Novartis AG , Sanofi SA , Teva Pharmaceutical Industries Ltd. and Roche Holding AG . Biogen shares declined 2.9% in heavy midday trade and Teva shares declined 1.1% in moderate trade. The lawmakers asked for information to evaluate multiple sclerosis drugs' "substantial price increases, including information about corporate profits and expenses and documents concerning pricing strategies, patient assistance programs, and drug distribution systems," and requested a response by the end of the month. The average price of a multiple sclerosis disease-modifying therapy rose from $16,000 in 2004 to about $84,000 in 2017, according to the National Multiple Sclerosis Society (the numbers refer to average wholesale price, which does not reflect often-substantial discounts and rebates). Prices for drugs sold by the seven drugmakers have increased by as much as 1,002% since 2012, according to information from the National Multiple Sclerosis Society cited by the two representatives. The lawmakers said that their letter referred to an American Academy of Neurology study that found "some drug companies appear to be increasing their prices and setting new, higher prices in lockstep in competitors," which may reflect a phenomenon called "shadow pricing" in which companies respond to eachothers' price increases. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/14/2017 15:26:44

    Tepper's Appaloosa dumps Snap Inc., stake, loads up on tech, health care

    David Tepper's hedge fund Appaloosa Management unloaded its position in Snapchat-parent Snap Inc., and disclosed increases in the tech and health-care sectors at the end of the second quarter. As of June 30, Tepper's fund showed that his fund dumped 100,000 shares of of Snap Inc. , which has lost more than a third of its value since it debuted as a public entity in early March. Tepper had been one of a number of prominent investors who had vocally expressed support of the social-messaging company. On Monday, Snap's shares were among the most active, gaining about 6.5% to start the week. Elsewhere, Appaloosa showed new positions in the PowerShares QQQ Trust Series 1 , which mimics the technology laden Nasdaq-100 , purchasing 1.8 million shares of the so-called QQQs, valued at $249 million, representing about 3.7% of his overall portfolio, according to data from research provider Whalewisdom.com. The fund also more than doubled its Apple Inc. position to 625,000 shares worth about $90 million and those of Altaba Inc. , which he boosted to 5.1 million shares valued at $280 million. Appaloosa showed a fresh stake in Alibaba Group Holding Limited , scooping up 3.6 million shares worth $520 million. Tepper's investment vehicle added a new position in exchange-traded IBB , a prominent ETF tracking the biotech sector, and SPDR S&P Biotech ETF , which closely mimics the S&P 500's health-care sector. Tepper's firm bought 235,000 shares of IBB worth about $73 million and 330,000 shares of XBI valued at $34 million, as of the end of June. In other sales, Tepper & Co. unloaded all of its position in Teva Pharmaceutical Industries , Energy Transfer Partners L.P. and Pfizer Inc. among others. Related: Active-managers have a new favorite toolMarket Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/14/2017 15:14:19

    Tepper's Appaloosa dumps Snap Inc. stake, loads up on tech, health care

    David Tepper's hedge fund Appaloosa Management unloaded its position in Snapchat-parent Snap Inc., and disclosed increases in the tech and health-care sectors at the end of the second quarter. As of June 30, Tepper's fund showed that his fund dumped 100,000 shares of of Snap Inc. , which has lost more than a third of its value since it debuted as a public entity in early March. Tepper had been one of a number of prominent investors who had vocally expressed support of the social-messaging company. On Monday, Snap's shares were among the most active, gaining about 6.5% to start the week. Elsewhere, Appaloosa showed new positions in the PowerShares QQQ Trust Series 1 , which mimics the technology laden Nasdaq-100 , purchasing 1.8 million shares of the so-called QQQs, valued at $249 million, representing about 3.7% of his overall portfolio, according to data from research provider Whalewisdom.com. The fund also more than doubled its Apple Inc. position to 625,000 shares worth about $90 million and those of Altaba Inc. , which he boosted to 5.1 million shares valued at $280 million. Appaloosa showed a fresh stake in Alibaba Group Holding Limited , scooping up 3.6 million shares worth $520 million. Tepper's investment vehicle added a new position in exchange-traded IBB , a prominent ETF tracking the biotech sector, and SPDR S&P Biotech ETF , which closely mimics the S&P 500's health-care sector. Tepper's firm bought 235,000 shares of IBB worth about $73 million and 330,000 shares of XBI valued at $34 million, as of the end of June. In other sales, Tepper & Co. unloaded all of its position in Teva Pharmaceutical Industries , Energy Transfer Partners L.P. and Pfizer Inc. among others.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    P.A.M. Transportation Services, Inc.PTSI | PACCAR Inc.PCAR | Pace Holdings Corp.PACEU | Pacific Biosciences of California, Inc.PACB | Pacific Continental Corporation (Ore)PCBK | Pacific DataVision, Inc.PDVW | Pacific Ethanol, Inc.PEIX | Pacific Mercantile BancorpPMBC | Pacific Premier Bancorp IncPPBI | Pacific Sunwear of California, Inc.PSUN |